We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly and South San Francisco, Calif.-headquartered TRexBio have inked a multi-year research collaboration and licensing deal potentially worth up to $1.1 billion to develop therapies for immune-mediated diseases. Read More
AstraZeneca announced a plan to purchase Waltham, Mass.-based CinCor Pharma in a deal worth up to $1.8 billion as it looks to expand its pipeline of heart and kidney drugs with CinCor’s hypertension candidate baxdrostat. Read More
Dutch biotech Synaffix has signed a $2 billion licensing agreement with Amgen to bring a new generation of antibody-drug conjugates (ADC) to market. Read More
Gilead Sciences is working to shore up its rheumatoid arthritis (RA) and lupus assets, teaming up with EVOQ Therapeutics to work on treatments for the two diseases. Read More
Drugmakers spent more than $68 billion for the top acquisitions in 2022 and the biggest buyout by far was Amgen’s, announced just weeks before the year’s end. Read More
Astellas Pharma, Pfizer’s Medivation subsidiary and Regents of the University of California have filed a lawsuit alleging that Sun Pharmaceutical infringed on a patent for their blockbuster prostate cancer drug Xtandi (enzalutamide). Read More
Gilead Sciences subsidiary Kite Pharma has entered into a purchase deal with Tmunity Therapeutics — the company founded by CAR-T cell pioneer Carl June — gaining access to Tmunity’s “armored” CAR-T cell platform. Read More